Literature DB >> 10379893

Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries.

V L Nelson1, R S Legro, J F Strauss, J M McAllister.   

Abstract

To test the hypothesis that the hyperandrogenemia associated with polycystic ovary syndrome (PCOS) results from an intrinsic abnormality in ovarian theca cell steroidogenesis, we examined steroid hormone production, steroidogenic enzyme activity, and mRNA expression in normal and PCOS theca cells propagated in long-term culture. Progesterone (P4), 17alpha-hydroxyprogesterone (17OHP4), and testosterone (T) production per cell were markedly increased in PCOS theca cell cultures. Moreover, basal and forskolin-stimulated pregnenolone, P4, and dehydroepiandrosterone metabolism were increased dramatically in PCOS theca cells. PCOS theca cells were capable of substantial metabolism of precursors into T, reflecting expression of an androgenic 17beta-hydroxysteroid dehydrogenase. Forskolin-stimulated cholesterol side chain cleavage enzyme (CYP11A) and 17alpha-hydroxylase/17,20-desmolase (CYP17) expression were augmented in PCOS theca cells compared with normal cells, whereas no differences were found in steroidogenic acute regulatory protein mRNA expression. Collectively, these observations establish that increased CYP11A and CYP17 mRNA expression, as well as increased CYP17, 3beta-hydroxysteroid dehydrogenase, and 17beta-hydroxysteroid dehydrogenase enzyme activity per theca cell, and consequently increased production of P4, 17OHP4, and T, are stable properties of PCOS theca cells. These findings are consistent with the notion that there is an intrinsic alteration in the steroidogenic activity of PCOS thecal cells that encompasses multiple steps in the biosynthetic pathway.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10379893     DOI: 10.1210/mend.13.6.0311

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  127 in total

Review 1.  The ovarian androgen-producing cells: a 2001 perspective.

Authors:  Denis A Magoffin
Journal:  Rev Endocr Metab Disord       Date:  2002-01       Impact factor: 6.514

2.  Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome.

Authors:  Marcus A Rosencrantz; Mickey S Coffler; Annette Haggan; Kimberly B Duke; Michael C Donohue; Rana F Shayya; H Irene Su; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2011-01-26       Impact factor: 5.958

Review 3.  Genetics of ovarian disorders: polycystic ovary syndrome.

Authors:  Stephen Franks; Mark McCarthy
Journal:  Rev Endocr Metab Disord       Date:  2004-03       Impact factor: 6.514

4.  Lipid-induced mononuclear cell cytokine secretion in the development of metabolic aberration and androgen excess in polycystic ovary syndrome.

Authors:  F González; R V Considine; O A Abdelhadi; A J Acton
Journal:  Hum Reprod       Date:  2020-05-01       Impact factor: 6.918

Review 5.  [Polycystic ovary syndrome. Prototype of a cardio-metabolic syndrome].

Authors:  D Heutling; H Schulz; H Randeva; C Dodt; H Lehnert
Journal:  Internist (Berl)       Date:  2007-02       Impact factor: 0.743

6.  The intraovarian actions of estrogen receptor-alpha are necessary to repress the formation of morphological and functional Leydig-like cells in the female gonad.

Authors:  John F Couse; Mariana M Yates; Karina F Rodriguez; Jo Anne Johnson; Donald Poirier; Kenneth S Korach
Journal:  Endocrinology       Date:  2006-04-20       Impact factor: 4.736

Review 7.  Neuroendocrine dysfunction in PCOS: a critique of recent reviews.

Authors:  Suhail A R Doi
Journal:  Clin Med Res       Date:  2008-09

Review 8.  The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum.

Authors:  Robert L Rosenfield
Journal:  J Pediatr Adolesc Gynecol       Date:  2014-08-27       Impact factor: 1.814

Review 9.  The role of TGF-β in polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Margrit Urbanek; Raymond J Rodgers; Richard S Legro
Journal:  Reprod Sci       Date:  2013-04-12       Impact factor: 3.060

Review 10.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.